Financial
Latest full-year results from official filings.
FY2025 revenue €19.63bn (+1.5%); operating margin 9.3%; net income €978.0m.
Net debt €9.20bn.
- Official results release · Fresenius Medical Care · 31 Dec 2025
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue €19.63bn (+1.5%); operating margin 9.3%; net income €978.0m.
Net debt €9.20bn.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
May 2025: TipRanks reported, from a company disclosure, that Fresenius Medical Care faced US FTC scrutiny over alleged anti-competitive practices alongside DaVita, and labour strikes in California linked to union-busting accusations.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches or cyber incidents involving Fresenius Medical Care found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Aug 2026: the FDA issued a warning letter over its Ogden, Utah plant, citing inadequate investigation of complaints about leaking peritoneal dialysis solution bags. Delflex solution had been recalled in Apr 2026 over lack of sterility assurance.
Contract delivery, go-lives, terminations and disputes.
Dec 2024: NHS England published an intention to directly award satellite adult dialysis services in Taunton, Yeovil and Frome (total about £12.7m, from Apr 2025) to the incumbent, with Fresenius Medical Care Renal Services (UK) listed as supplier.